Browse

Dr. Johann De Bono and Dr. Pedro Barata discuss the evolving role of treatment sequencing and patient selection for radiopharmaceuticals in metastatic castration-resistant prostate cancer (mCRPC).

Dr. Pedro Barata and Dr. Johann De Bono discuss how patient selection and disease characteristics influence the use of radiopharmaceuticals in metastatic castration-resistant prostate cancer (mCRPC).

Dr. Johann De Bono and Dr. Pedro Barata discuss the evolving role of alpha-emitting radiopharmaceutical therapies in metastatic castration-resistant prostate cancer (mCRPC), with a focus on radium…